Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Genmab A/S
Genmab designs antibody drugs for cancer and other diseases, selling them to patients and partnering with big pharma companies.
Genmab is a Danish biotech company that makes antibody medicines, mostly for cancer. Antibodies are the body's natural targeting missiles — proteins that latch onto a specific thing, like a flag on the surface of a cancer cell. Genmab engineers versions of these proteins that either flag sick cells for the immune system to destroy or deliver a toxic payload straight to a tumor. Its medicines reach patients in two main ways: Genmab sells some drugs itself, and it hands others to big partners who handle the marketing and pay Genmab royalties on sales.
The crown jewel is Darzalex, a treatment for multiple myeloma, a cancer of the blood. Genmab invented it and licensed it to Johnson & Johnson, which turned it into a multibillion-dollar blockbuster. That partnership is the clearest illustration of how Genmab's model works: it does the hard scientific work, then lets a giant with global sales muscle do the selling while Genmab collects a royalty stream. Genmab also has its own approved medicines, including Epkinly for certain lymphomas, plus a pipeline of experimental drugs in earlier stages. The business has shifted over time. For years Genmab was essentially a royalty collector — brilliant science, but dependent on partners. More recently it has built up its own commercial operation, and it made a bold bet in 2024 by buying ProfoundBio, a private biotech, for about $1.8 billion to get its hands on next-generation antibody-drug conjugates. Those are antibodies loaded with chemo, a hot area of cancer research. Buying a private company with no approved products is a riskier move than collecting royalties, but it gives Genmab more control over its future.
The honest weakness is concentration. A huge share of the company's value still rides on Darzalex and its royalties, so anything that threatens that drug — competition, pricing pressure, or a clinical setback — hits Genmab hard. Partners also capture a lot of the upside that Genmab's own scientists created. Genmab is based in Copenhagen and listed there, and it uses its cash to fund research, strike deals, and buy back shares rather than pay a big dividend.
Saved answer · last researched 12 Nov 2026